Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05437094 · ClinicalTrials.gov registry record · Phase 1
Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740
A Phase 1 study, sponsored by Cardurion Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 20
- Enrollment target
NCT05437094 is a Phase 1 study that has completed, run by Cardurion Pharmaceuticals. The registered enrollment target is 20 participants.
The verdict
NCT05437094, a Phase 1 study, has completed, sponsored by Cardurion Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 20 participants
- Enrollment target
Study Summary
This is a Phase 1, single-site, open-label, fixed sequence crossover study to investigate the effect of coadministration of itraconazole on the pharmacokinetics of CRD-740 in healthy male and female subjects. Subjects will be admitted into the study site on Day -1 and will be confined to the study site until discharge on Day 16. Subjects will receive CRD-740 orally on Days 1 and 10. Itraconazole will be given once daily, orally, on Days 7 through 15.
Interventions
- DRUG Itraconazole
- DRUG CRD-740
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2022-06-27 |
| Est. Completion | 2022-08-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05437094
The ClinicalTrials.gov registry entry for NCT05437094 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cardurion Pharmaceuticals, which has 9 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Itraconazole is the first listed.
NCT05437094 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05437094 about?
NCT05437094 is a clinical study titled "Effect of Coadministration of Itraconazole on the Pharmacokinetics of CRD-740". This is a Phase 1, single-site, open-label, fixed sequence crossover study to investigate the effect of coadministration of itraconazole on the pharmacokinetics of CRD-740 in healthy male and female subjects. Subjects will be admitted into the study site on Day -1 and will be confined to the study s...
What is the current status of trial NCT05437094?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 20 participants. The study started on 2022-06-27. Estimated completion is 2022-08-10.
What interventions are being tested in trial NCT05437094?
The interventions under investigation include: Itraconazole (DRUG), CRD-740 (DRUG).
Who is sponsoring clinical trial NCT05437094?
This trial is sponsored by Cardurion Pharmaceuticals, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.